Strong trader consensus for "No" at 95% reflects sustained moderate global risk from SARS-CoV-2 as of mid-2026, with ongoing low-level circulation of JN.1-descendant variants and BA.3.2 under monitoring by WHO and CDC, rather than conditions meeting pandemic criteria. High population hybrid immunity from prior infections and vaccination has limited severe outcomes, keeping test positivity below 5% in many systems and hospitalizations aligned with seasonal patterns without overwhelming health infrastructure. Official assessments show no evidence of markedly increased transmissibility or virulence in current strains. Realistic challenges include emergence of a novel variant with substantial immune escape and higher severity, or a zoonotic spillover of another coronavirus capable of efficient human-to-human transmission.